King Star Med

King Star Med deploys capital across venture and growth stages, targeting healthcare companies from early-stage innovation through commercial-stage scale-ups. The firm evaluates opportunities where regulatory milestones — such as FDA clearance or CE marking — act as value-inflection points. Specific stage allocations and check sizes are not publicly disclosed.

The firm concentrates on medical technology, digital health platforms, and healthcare services. This spans device companies navigating regulatory pathways, software-enabled clinical workflow platforms, and services businesses with scalable reimbursement models. The firm has not published a formal negative screen for subsectors it avoids.

The Cayman Islands domicile provides a tax-neutral fund structure that accommodates international limited partners investing into operating companies across multiple jurisdictions. This structure separates fund-level taxation from the portfolio companies' home countries, a common arrangement for private equity vehicles with cross-border LP bases and portfolio holdings in the US, Europe, and Asia.

The firm's Cayman Islands fund structure implies pooled investment vehicles open to qualified institutional and individual investors. However, King Star Med has not publicly disclosed its LP base, minimum commitment sizes, or whether it maintains a single-family office component alongside third-party capital.

The firm has not publicly reported portfolio exits, realized returns, or fund-level performance metrics. Without disclosed deal history or regulatory filings that would reveal ownership changes in named portfolio companies, the track record remains opaque to external evaluators.